Manufacturing

Lilly to acquire Loxo Oncology for $8bn

Eli Lilly and Company (Lilly) has agreed to acquire Connecticut-based biopharmaceutical company Loxo Oncology in an all-cash deal worth $8bn.

Catalent to invest $200m in biologics business

Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has started a $200m capital investment to expand biologics capacity and capabilities.

Bristol-Myers Squibb to acquire Celgene for $74bn

Pharma giant Bristol-Myers Squibb has agreed to acquire US biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.

Portola secures FDA approval for Andexxa generation 2 manufacturing process

The US Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for the manufacturing process of second generation Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].

Pfizer, GSK to create $13bn consumer healthcare joint venture

Pfizer and the UK-based GlaxoSmithKline (GSK) have agreed to merge their respective consumer healthcare businesses into a new joint venture (JV), which will be majority owned by the latter.

AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma

AstraZeneca has completed its $350m sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma.

Cambrex to acquire contract drug developer Avista Pharma for $252m

Life sciences company Cambrex has agreed to acquire Avista Pharma Solutions, a North Carolina-based contract development, manufacturing, and testing organization, for about $252m.

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

AstraZeneca has agreed to offload its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for $350m.

Quotient Sciences extends formulation and manufacturing operations in UK

Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading facility, UK.